Interpretation of the 5th edition of WHO classification of endocrine and neuroendocrine tumors: update and progress on follicular cell-derived thyroid tumors

Abstract

Abstract:

The 2022 WHO classification of endocrine and neuroendocrine tumors (5th edition) categorizes thyroid follicular cell-derived tumors into benign, low-risk, and malignant types. Benign tumors now include thyroid follicular nodular lesions. A newly added category previously termed "borderline tumors" have been revised to low-risk follicular cell-derived tumors, which encompass non-invasive follicular thyroid neoplasm with papillary-like nuclear features, thyroid tumors of uncertain malignant potential, and hyalinizing trabecular tumors. The new WHO classification stratifies malignant follicular cell-derived tumors based on molecular characteristics and invasiveness: papillary thyroid carcinoma (PTC) with various histological subtypes represents BRAF-like malignancies; invasive encapsulated follicular variant PTC and follicular thyroid carcinoma represent RAS-like malignancies. Oncocytic carcinoma is now recognized as a distinct entity, specifically referring to tumors composed of ≥75% oncocytic follicular cells lacking PTC nuclear features and high-grade characteristics (necrosis and mitotic figures ≥3/2 mm²). A new category termed "high-grade follicular cell-derived thyroid carcinoma" has been added, encompassing traditional poorly differentiated thyroid carcinoma and differentiated high-grade thyroid carcinoma. Anaplastic thyroid carcinoma(ATC) remains the most undifferentiated type, with thyroid squamous cell carcinoma now classified as a subtype of ATC. The term "papillary thyroid microcarcinoma" is no longer recommended as a distinct subtype. Cribriform-morular thyroid carcinoma is no longer classified as a subtype of PTC, but is instead categorized as a tumor of uncertain histogenesis.

Key words:Thyroid tumor,Thyroid follicular cell,Endocrine and neuroendocrine tumor,Tumor classification,Pathological diagnosis

CLC Number:

R736.1

LU Shanshan, JI Yuan. Interpretation of the 5th edition of WHO classification of endocrine and neuroendocrine tumors: update and progress on follicular cell-derived thyroid tumors[J]. Journal of Surgery Concepts & Practice, 2025, 30(01): 27-33.

References29

[1]	ASA S L. The current histologic classification of thyroid cancer[J].Endocrinol Metab Clin North Am,2019,48(1):1-22.
[2]	KAMILARIS C D C, FAUCZ F R, VOUTETAKIS A, et al. Carney complex[J].Exp Clin Endocrinol Diabetes,2019,127(2-3):156-164.
[3]	DOERFLER W R, NIKITSKI A V, MORARIU E M, et al. Molecular alterations in Hürthle cell nodules and pre-operative cancer risk[J].Endocr Relat Cancer,2021,28(5):301-309.
[4]	中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J].国际内分泌代谢杂志,2023,43(2):149-194.
	Chinese Society of Endocrinology, Chinese Society of Surgery, Thyroid and Metabolic Surgery Group, Head and Neck Tumor Committee of Chinese Anti-Cancer Association, et al. Guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer (se-cond edition)[J].Int J Endocrinol Metab,2023,43(2):149-194.
[5]	XU B, FARHAT N, BARLETTA J A, et al. Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?[J].Endocrine,2018,59(1):143-150. doi:10.1007/s12020-017-1484-1pmid:29204912
[6]	XU B, TALLINI G, SCOGNAMIGLIO T, et al. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J].Thyroid,2017,27(4):512-517. doi:10.1089/thy.2016.0649pmid:28136139
[7]	NIKIFOROVA M N, NIKIFOROV Y E, OHORI N P. GLIS rearrangements in thyroid nodules: a key to pre-operative diagnosis of hyalinizing trabecular tumor[J].Cancer Cytopathol,2019,127(9):560-566.
[8]	刘志艳, 觉道健一. 第五版WHO甲状腺肿瘤分类中低风险肿瘤的解读[J].中华医学杂志,2022,102(48):3806-3810.
	LIU Z Y, KYUDO KENICHI. Interpretation of low-risk neoplasms in the 5th edition of WHO classification of thyroid tumors[J].Natl Med J China,2022,102(48):3806-3810.
[9]	BALOCH Z W, ASA S L, BARLETTA J A, et al. Overview of the 2022 WHO classification of thyroid neoplasms[J].Endocr Pathol,2022,33(1):27-63. doi:10.1007/s12022-022-09707-3pmid:35288841
[10]	CARNEY J A, HIROKAWA M, LLOYD R V, et al. Hyalinizing trabecular tumors of the thyroid gland are almost all benign[J].Am J Surg Pathol,2008,32(12):1877-1889. doi:10.1097/PAS.0b013e31817a8f1bpmid:18813121
[11]	CARCANGIU M L, ZAMPI G, ROSAI J. Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates[J].Pathol Annu,1985,20 Pt1:1-44.
[12]	JANJUA N, WREESMANN V B. Aggressive differen-tiated thyroid cancer[J].Eur J Surg Oncol,2018,44(3):367-377.
[13]	YANG F, ZHONG Q, HUANG Z, et al. Survival in papillary thyroid microcarcinoma: a comparative analysis between the 7th and 8th versions of the AJCC/UICC staging system based on the SEER database[J].Front Endocrinol (Lausanne),2019,10:10.
[14]	KURE S, OHASHI R. Thyroid Hürthle cell carcinoma: clinical, pathological, and molecular features[J].Cancers (Basel),2020,13(1):26.
[15]	RASHID F A, MUNKHDELGER J, FUKUOKA J, et al. Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review[J].Gland Surg,2020,9(5):1878-1900.
[16]	XING M, LIU R, LIU X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726. doi:10.1200/JCO.2014.55.5094pmid:25024077
[17]	CAUDILL C M, ZHU Z, CIAMPI R, et al. Dose-dependent generation of RET/PTC in human thyroid cells afterin vitroexposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation[J].J Clin Endocrinol Metab,2005,90(4):2364-2369.
[18]	PEKOVA B, SYKOROVA V, MASTNIKOVA K, et al. NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis[J].Cancers(Basel),2021,13(8):1932.
[19]	RAMAN P, KOENIG R J. Pax-8-PPAR-γ fusion protein in thyroid carcinoma[J].Nat Rev Endocrinol,2014,10(10):616-623. doi:10.1038/nrendo.2014.115pmid:25069464
[20]	BAE J S, JUNG S H, HIROKAWA M, et al. High prevalence of DICER1 mutations and low frequency of gene fusions in pediatric follicular-patterned tumors of the thyroid[J].Endocr Pathol,2021,32(3):336-346.
[21]	PAULSSON J O, RAFATI N, DILORENZO S, et al. Whole-genome sequencing of follicular thyroid carcinomas reveal recurrent mutations in microRNA processing subunit DGCR8[J].J Clin Endocrinol Metab,2021,106(11):3265-3282. doi:10.1210/clinem/dgab471pmid:34171097
[22]	CHINDRIS A M, CASLER J D, BERNET V J, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid[J].J Clin Endocrinol Metab,2015,100(1):55-62.
[23]	周隽, 刘志艳. 第5版WHO高级别甲状腺滤泡源性癌病理诊断标准及特征解读[J].中华医学杂志,2024,104(18):1578-1583.
	ZHOU J, LIU Z Y. Interpretation of the pathological diagnostic criteria and characteristics of high-grade thyroid follicular-derived carcinoma in the 5 th edition WHO classification[J].Natl Med J China,2024,104(18):1578-1583.
[24]	XU B, DAVID J, DOGAN S, et al. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases[J].Histopathology,2022,80(2):322-337.
[25]	CHERNOCK R D, RIVERA B, BORRELLI N, et al. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations[J].Mod Pathol,2020,33(7):1264-1274.
[26]	XU B, IBRAHIMPASIC T, WANG L, et al. Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas[J].Thyroid,2016,26(11):1588-1597. pmid:27480016
[27]	WONG K S, DONG F, TELATAR M, et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome[J].Thyroid,2021,31(6):933-940. doi:10.1089/thy.2020.0668pmid:33143568
[28]	GNEMMI V, RENAUD F, DO CAO C, et al. Poorly diffe-rentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high-grade features[J].Histopathology,2014,64(2):263-273.
[29]	POZDEYEV N, GAY L M, SOKOL E S, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers[J].Clin Cancer Res,2018,24(13):3059-3068. doi:10.1158/1078-0432.CCR-18-0373pmid:29615459